Understanding Vogt-Koyanagi-Harada Syndrome
Understanding VKH Syndrome
VKH is a bilateral granulomatous panuveitis, meaning it causes widespread inflammation inside both eyes at the same time. The inflammation centers on the uvea, the pigmented middle layer of the eye that includes the iris, ciliary body, and choroid. In VKH, the immune system mistakenly attacks melanocytes, the cells responsible for pigmentation in the eyes, skin, inner ear, and the membranes covering the brain and spinal cord.
Because melanocytes are found in many organs, VKH is considered a multisystem disease. Patients may develop serous retinal detachments (fluid buildup beneath the retina), hearing changes, headaches, and skin or hair color changes.
VKH is thought to begin when the immune system loses its normal tolerance to melanocyte proteins. T-cells, a type of white blood cell, become sensitized to melanocyte antigens such as tyrosinase and tyrosinase-related peptides. This triggers an inflammatory cascade that damages melanocyte-rich tissues. Researchers believe a genetic predisposition combined with a possible infection or environmental trigger sets this autoimmune process in motion.
VKH typically progresses through four recognized stages, though not every patient experiences all of them.
- Prodromal stage: Flu-like symptoms such as headache, fever, nausea, and neck stiffness appear days before eye involvement. Some patients also notice dizziness or ringing in the ears.
- Acute uveitic stage: Severe bilateral eye inflammation develops, often with blurred vision, light sensitivity, and serous retinal detachments visible on examination.
- Convalescent stage: Eye inflammation begins to subside, but skin and hair changes such as vitiligo (loss of skin pigment) and poliosis (whitening of eyelashes or eyebrows) may emerge.
- Chronic recurrent stage: Some patients experience repeated flares of eye inflammation, which can lead to complications if not managed carefully.
Who Is Affected and Risk Factors
VKH predominantly affects individuals with darker pigmentation. Those of Asian, Hispanic, Middle Eastern, and Native American descent have the highest rates of the disease. In the United States, VKH accounts for roughly 1% to 4% of uveitis referrals (AAO EyeWiki). The annual incidence in the United States has been estimated at approximately 1 in 267,000 people (Orphanet).
The mean age of onset is around 30 years, although cases have been reported in individuals ranging from 10 to 52 years of age. The majority of cases occur between the second and fifth decades of life. VKH is found more often in women than in men.
Several human leukocyte antigen (HLA) associations have been identified in VKH patients. Among Japanese patients, HLA-DR4, HLA-DR53, and HLA-DQ4 are strongly associated with the disease. In Chinese patients, associations include HLA-DR4, HLA-DR53, and HLA-DQ7. These genetic markers suggest that inherited immune system characteristics influence who develops VKH, though having these markers does not guarantee the disease will occur.
Signs and Symptoms
Before the eyes become visibly affected, many patients experience several days of symptoms that resemble a viral illness. These may include headache, fever, orbital pain (pain around the eyes), nausea, dizziness, and neck stiffness. Some patients develop tinnitus (ringing in the ears), vertigo, or mild hearing loss during this phase. These symptoms reflect inflammation of the meninges, the membranes surrounding the brain and spinal cord.
During the acute uveitic stage, patients typically notice rapid vision changes in both eyes. Common complaints include significant light sensitivity, blurred or dimming vision, and floaters. A retina specialist examining the eye may observe multiple serous retinal detachments, vitreous cells (inflammatory cells floating in the gel inside the eye), and subretinal fluid with fibrinous septa on optical coherence tomography (OCT) imaging.
As VKH progresses into the convalescent stage, some patients develop vitiligo, which appears as patches of depigmented skin. Poliosis, or whitening of the eyelashes, eyebrows, or scalp hair, may also occur. Hearing changes, including persistent tinnitus or partial hearing loss, can develop at any stage. These extraocular signs help distinguish VKH from other forms of uveitis.
In some cases, neurologic involvement goes beyond headache and neck stiffness. Rarely, patients may experience confusion, seizures, weakness on one side of the body, difficulty speaking, or cranial nerve problems. These serious neurologic signs require urgent medical evaluation.
Diagnosis and Testing
A retina specialist diagnoses VKH based on a combination of clinical findings, patient history, and imaging results. The hallmark finding is bilateral panuveitis with serous retinal detachments. A thorough history that reveals neurologic, auditory, or skin changes strongly supports the diagnosis. The revised diagnostic criteria classify VKH as complete, incomplete, or probable based on the presence or absence of extraocular manifestations.
Several imaging techniques help confirm the diagnosis and monitor the disease.
- Optical coherence tomography (OCT): This non-invasive scan reveals characteristic subretinal fluid pockets with fibrinous septa and can track fluid resolution during treatment.
- Fluorescein angiography (FA): This dye-based test shows multiple areas of fluid leakage at the level of the retinal pigment epithelium, often in a pattern described as multiple pinpoint leaks.
- Indocyanine green angiography (ICGA): This test detects choroidal (the vascular layer beneath the retina) inflammation even when it is not visible on standard examination.
- Ultrasound: B-scan ultrasonography may show diffuse choroidal thickening, especially when dense inflammation makes it difficult to view the retina directly.
Because several conditions can mimic VKH, a retina specialist may order blood tests, lumbar puncture (spinal tap), or other studies to exclude infections such as syphilis or tuberculosis, as well as other causes of bilateral uveitis. A lumbar puncture in VKH patients often reveals cerebrospinal fluid pleocytosis (an elevated white blood cell count in the spinal fluid), which provides additional diagnostic support.
Treatment Options
The initial treatment for acute VKH typically involves high-dose systemic corticosteroids. Intravenous or oral corticosteroids are started promptly to suppress the intense inflammation. The goal is to resolve the serous retinal detachments and reduce intraocular inflammation as quickly as possible. Corticosteroids are then slowly tapered over several months. Rapid tapering carries a significant risk of relapse. Studies report recurrence rates of 43% within the first three months and 52% within the first six months, often linked to corticosteroid doses being reduced too quickly (AAO EyeNet).
Because long-term high-dose corticosteroids cause serious side effects, retina specialists frequently add steroid-sparing immunomodulatory therapy (IMT). Methotrexate and mycophenolate mofetil are the most commonly used first-line immunomodulators. Research comparing these two agents found them to be comparable overall, though methotrexate showed a greater reduction in retinal central subfield thickness and was superior for resolving subretinal fluid (AAO EyeNet). A small prospective study also demonstrated that patients treated with mycophenolate mofetil plus systemic corticosteroids had better visual acuity and fewer recurrences than those treated with corticosteroids alone.
For patients who do not respond adequately to conventional immunomodulators, biologic agents may be considered. Adalimumab (Humira) was the first anti-tumor necrosis factor alpha (anti-TNF-alpha) antibody approved by the FDA for non-infectious intermediate, posterior, and panuveitis, based on the landmark VISUAL I and VISUAL II clinical trials in 2016. Infliximab is another biologic used in refractory cases. In surveys of uveitis specialists, adalimumab and infliximab were rated as the most effective treatments for VKH, although they are often reserved for cases that fail first-line immunomodulators.
Recent research supports starting immunomodulatory therapy early in the course of VKH rather than waiting for corticosteroid failure. A South Korean study found that adding immunomodulatory therapy within three months of disease onset was associated with improved long-term visual acuity compared with conventional treatment. Other reports suggest that starting steroid-sparing immunosuppressive therapy within two to three weeks of onset may help prevent progression to the chronic recurrent stage. Mycophenolate mofetil and mycophenolic acid have been found to help prevent the onset of chronic VKH when used early.
What to Expect
Patients in the acute phase often experience significant vision loss in both eyes. With prompt high-dose corticosteroid treatment, serous retinal detachments typically begin to resolve within days to weeks. Frequent monitoring with OCT and clinical examination helps the retina specialist track fluid absorption and adjust treatment. Patients should expect multiple office visits during this period.
VKH often requires months to years of immunosuppressive therapy. The corticosteroid taper is slow and carefully monitored, and immunomodulatory medications may be continued for an extended period to prevent recurrence. Regular blood tests are needed to monitor for side effects of these medications. Many patients achieve stable disease control with consistent treatment, but skipping doses or stopping medication without guidance from a retina specialist can trigger a relapse.
When VKH is not adequately controlled, several complications can develop over time.
- Cataracts (clouding of the natural lens), which may result from the disease itself or prolonged corticosteroid use.
- Glaucoma (elevated eye pressure), which can damage the optic nerve if untreated.
- Choroidal neovascularization (abnormal blood vessel growth beneath the retina), which may require additional treatment such as intravitreal anti-VEGF injections.
- Subretinal fibrosis (scarring beneath the retina), which can cause permanent vision loss.
- Sunset glow fundus, a characteristic pale orange appearance of the retina caused by loss of pigment in the choroid.
Living with VKH Syndrome
Even after inflammation is controlled, patients with VKH need regular follow-up appointments with a retina specialist. Chronic, low-grade inflammation can persist without obvious symptoms, and imaging may detect subtle changes before a patient notices any vision loss. Monitoring for complications such as glaucoma and cataracts is also part of routine care.
Because immunosuppressive medications affect the entire immune system, patients should stay up to date on vaccinations as recommended by their primary care provider and report any signs of infection promptly. Regular blood work helps ensure that medications are not causing liver, kidney, or blood cell abnormalities. Coordination between the retina specialist and other physicians is important for safe long-term management.
Living with a chronic inflammatory condition that affects vision, hearing, and appearance can be emotionally challenging. Patients may benefit from connecting with support groups for uveitis or autoimmune conditions. Adjusting to changes in skin and hair pigmentation, managing light sensitivity with quality sunglasses, and using assistive devices for any hearing changes can help maintain quality of life.
When to See a Retina Specialist
Certain symptoms require immediate evaluation by a retina specialist or an emergency room visit. These include sudden vision loss or significant blurring in one or both eyes, a sudden increase in floaters, flashes of light, or a curtain or shadow moving across the field of vision. In VKH specifically, the combination of bilateral vision changes with headache, hearing changes, or skin depigmentation should prompt urgent medical attention.
Any patient diagnosed with bilateral uveitis, especially with associated neurologic or systemic symptoms, should be referred to a retina specialist experienced in managing inflammatory eye diseases. Early referral allows for timely diagnosis and treatment, which is associated with better visual outcomes. Patients already diagnosed with VKH who notice new symptoms or worsening vision between scheduled appointments should contact their retina specialist promptly.
Questions and Answers
VKH is a chronic autoimmune condition that can be managed effectively but is not considered curable. The goal of treatment is to control inflammation, prevent recurrences, and preserve as much vision as possible. Many patients achieve long-term remission with consistent immunosuppressive therapy, but ongoing monitoring remains important because the disease can recur even after years of stability.
The primary treatment for VKH involves systemic medications taken by mouth or through an intravenous line, not intravitreal injections. However, if a complication such as choroidal neovascularization develops, a retina specialist may recommend anti-VEGF injections to treat the abnormal blood vessels. Local corticosteroid injections around or inside the eye may also be used in certain situations to supplement systemic therapy.
The duration of immunosuppressive therapy varies from patient to patient. Many retina specialists recommend continuing treatment for at least two years after inflammation is fully controlled before considering a very gradual taper. Some patients require longer courses. Stopping medication too early is one of the most common reasons for disease recurrence, so any changes to the treatment plan should be made in close consultation with a retina specialist.
VKH is by definition a bilateral disease, meaning it affects both eyes. However, the severity of inflammation and the degree of vision loss may differ between the two eyes. One eye may develop serous retinal detachments or complications sooner or more severely than the other. Treatment targets both eyes simultaneously to reduce the overall inflammatory burden.
While certain HLA genetic markers are associated with VKH, having a parent with the condition does not mean a child will develop it. VKH requires both a genetic predisposition and an environmental or immunologic trigger. The disease is not inherited in a simple pattern. If family members develop bilateral eye inflammation or unexplained vision and hearing changes, they should be evaluated by a retina specialist.